Compare GOLF & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOLF | DFTX |
|---|---|---|
| Founded | 1910 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.9B |
| IPO Year | 2016 | 2020 |
| Metric | GOLF | DFTX |
|---|---|---|
| Price | $89.59 | $42.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $83.67 | $38.50 |
| AVG Volume (30 Days) | 336.6K | ★ 2.1M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.44 | N/A |
| Revenue | ★ $1,633,721,000.00 | N/A |
| Revenue This Year | $5.76 | N/A |
| Revenue Next Year | $2.44 | N/A |
| P/E Ratio | $26.17 | ★ N/A |
| Revenue Growth | ★ 4.71 | N/A |
| 52 Week Low | $73.09 | $14.62 |
| 52 Week High | $119.65 | $49.70 |
| Indicator | GOLF | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 26.25 | 49.67 |
| Support Level | $86.26 | $40.29 |
| Resistance Level | $92.18 | $49.13 |
| Average True Range (ATR) | 4.54 | 2.71 |
| MACD | -1.42 | -0.50 |
| Stochastic Oscillator | 3.93 | 22.69 |
Acushnet Holdings Corp is engaged in the design, development, manufacture, and distribution of golf products. Its product category includes golf balls, golf shoes, golf clubs, wedges, putters, golf gloves, golf gear and golf wear, and others. These products are offered through different brands such as Titleist, FootJoy, Scotty Cemeron, Vokey Design, Pinnacle, KJUS, and others. The company's reportable segments are Titleist golf equipment, FootJoy golf wear, and Gofl gear. A majority of its revenue is generated by the Titleist golf equipment segment. Geographically, the company generates maximum revenue from the United States, followed by Europe, Middle East and Asia (EMEA), Japan, Korea, and the Rest of the world.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.